Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by CANbridge Pharmaceuticals, Inc.
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee
July 03, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
June 26, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
May 04, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy annual Meeting
April 11, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022
March 30, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
March 27, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
March 16, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China
January 18, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Consolidates Gene Therapy Portfolio
January 03, 2023
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the Treatment of Myasthenia Gravis
November 15, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences
October 12, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Data on CAN106 to be Presented at Two Conferences
September 23, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September
September 12, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022
August 24, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress
May 12, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Appoints Pauline Li as Senior Vice President of Clinical Development and Operations
May 11, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
March 27, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021
March 22, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CORRECTING and REPLACING CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
February 25, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
February 24, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Appoints Dr. Lan Hu as New Independent Director
February 16, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Reports Positive Top-Line CAN106 Phase 1 Data
February 07, 2022
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
The Chinese Red Cross Foundation Rare Disease Mutual Assistance Fund Officially Launches
December 19, 2021
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Ltd Listed on Main Board of Hong Kong Stock Exchange
December 09, 2021
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Signs Collaboration Agreement with the Peking Union Medical College on Rare Disease Research
December 09, 2021
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CORRECTING and REPLACING First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China
October 26, 2021
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China
October 26, 2021
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals Enters into Exclusive Worldwide Research Collaboration and Licensing Agreement with Scriptr Global for Stitchr™ RNA Assembly Technology to Develop Gene Therapy Product Targeting Dystrophinopathies
October 25, 2021
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor
May 12, 2021
From
CANbridge Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.